130 related articles for article (PubMed ID: 18062726)
1. Darunavir in the treatment of HIV-1 infection: a viewpoint by Renslow Sherer.
Sherer R
Drugs; 2007; 67(18):2802-3. PubMed ID: 18062726
[No Abstract] [Full Text] [Related]
2. Darunavir in the treatment of HIV-1 infection: a viewpoint by Mark Holodniy.
Holodniy M
Drugs; 2007; 67(18):2803. PubMed ID: 18062725
[No Abstract] [Full Text] [Related]
3. [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():24-5. PubMed ID: 19024912
[No Abstract] [Full Text] [Related]
4. New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.
Rotty J; Hoy J
Sex Health; 2008 Sep; 5(3):235-41. PubMed ID: 18771638
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV agents. Darunavir shows its strength.
TreatmentUpdate; 2007; 19(5):2-4. PubMed ID: 17955613
[No Abstract] [Full Text] [Related]
6. Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.
Poveda E; Vispo E; Pattery T; de Mendoza C; Villacian J; Soriano V
J Antimicrob Chemother; 2007 Dec; 60(6):1411-3. PubMed ID: 17911388
[No Abstract] [Full Text] [Related]
7. Darunavir.
El-Atrouni WI; Temesgen Z
Drugs Today (Barc); 2007 Oct; 43(10):671-9. PubMed ID: 17987220
[TBL] [Abstract][Full Text] [Related]
8. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
[No Abstract] [Full Text] [Related]
9. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
10. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
[No Abstract] [Full Text] [Related]
11. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
12. [Position of darunavir in antiretroviral therapy].
Clotet B
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():61-2. PubMed ID: 19195461
[No Abstract] [Full Text] [Related]
13. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
[TBL] [Abstract][Full Text] [Related]
14. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
[No Abstract] [Full Text] [Related]
15. New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M; Cartledge JD
J HIV Ther; 2008 Jun; 13(2):40-4. PubMed ID: 18953273
[No Abstract] [Full Text] [Related]
16. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
17. Efficacy of a reduced dose of darunavir/ritonavir in a small cohort of antiretroviral-naïve HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Vento S
AIDS Patient Care STDS; 2013 Jun; 27(6):315-6. PubMed ID: 23701201
[No Abstract] [Full Text] [Related]
18. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
[TBL] [Abstract][Full Text] [Related]
19. 48-week study results show DRV's staying power.
Bernard EJ
IAPAC Mon; 2007 Jan; 13(1):10-1. PubMed ID: 17523243
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]